SCHEMBL13624279

SCHEMBL13624279

N#Cc1ccccc1-c1ccc(CN2C(=O)S/C(=C\c3ccc(O)c(C(F)(F)F)c3)C2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.54
▸ PIM1 P11309 1/20 0.47
▸ PTPN1 P18031 7/20 0.46
▸ ACP1 P24666 7/20 0.46
▸ PPARG P37231 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ PTPN2 P17706 2/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ CASP3 P42574 1/20 0.44
▸ SENP8 Q96LD8 1/20 0.44
▸ SENP7 Q9BQF6 1/20 0.44
▸ SENP6 Q9GZR1 1/20 0.44
▸ NLRP3 Q96P20 1/20 0.44
▸ ENPP2 Q13822 4/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CRHBP P24387 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172012 1.00 SLC2A1 (0.54) SLC2A1PIM1PTPN1ACP1PPARG
SCHEMBL2172015 1.00 SLC2A1 (0.54) SLC2A1PIM1PTPN1ACP1PPARG
SCHEMBL12406548 0.91 PIM1 (0.47) SLC2A1PIM1PTPN1ACP1PPARG
SCHEMBL2172758 0.87 HSD17B3 (0.51) PTPN1ACP1PPARGMEN1POLB
SCHEMBL2172764 0.87 HSD17B3 (0.51) PTPN1ACP1PPARGMEN1POLB
SCHEMBL12406497 0.86 SLC2A1 (0.61) SLC2A1PIM1PTPN1ACP1MEN1
SCHEMBL2175486 0.86 SLC2A1 (0.61) SLC2A1PIM1PTPN1ACP1MEN1
SCHEMBL2175489 0.86 SLC2A1 (0.61) SLC2A1PIM1PTPN1ACP1MEN1
SCHEMBL1614982 0.84 SLC2A1 (0.66) SLC2A1PIM1PTPN1ACP1PPARG
SCHEMBL2171655 0.84 SLC2A1 (0.66) SLC2A1PIM1PTPN1ACP1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-11-26 — — US disclosed
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-11-26 — — US disclosed
WO-2009105621-A1 ANDROGEN RECEPTOT-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-08-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS AR, ESRRB, KLK3 SLC2A1 2158/4885PIM1 4023/4885PTPN1 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback